4.5 Review

EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy

期刊

EXPERT OPINION ON THERAPEUTIC TARGETS
卷 15, 期 1, 页码 63-74

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1517/14728222.2011.541440

关键词

Akt; EGFR; head and neck squamous cell carcinoma; mTOR; PI3K; targeted therapy

资金

  1. NIDCD [ZIA-DC-000073]
  2. NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [K08DC000073, ZIADC000073] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Importance of the field: Recent advances in the understanding of the oncogenesis of head and neck squamous cell carcinomas (HNSCC) have revealed multiple dysregulated signaling pathways. One frequently altered axis is the EGFR-PI3K-Akt-mTOR pathway. This pathway plays a central role in numerous cellular processes including metabolism, cell growth, apoptosis, survival and differentiation, which ultimately contributes to HNSCC progression. Areas covered in this review: Books, journals, databases and websites have been searched to provide a current review on the subject. What the reader will gain: This article reviews the current understanding of EGFR-PI3K-Akt-mTOR signaling in HNSCC, including the impact of both genetic and epigenetic alterations. This review further highlights the potential of targeting this signaling cascade as a promising therapeutic approach in the treatment of HNSCC. Take home message: Genetic alterations of several nodes within this pathway, including both genetic and epigenetic changes, leading to either oncogene activation or inactivation of tumor suppressors have frequently been implicated in HNSCC. Consequently, drugs that target the central nodes of this pathway have become attractive for molecular oriented cancer therapies. Numerous preclinical and clinical studies are being performed in HNSCC; however, more studies are still needed to better understand the biology of this pathway.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据